Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.
ImmunityBio Inc. plans to target a large chunk of the bladder cancer population with its newly approved immuno-oncology drug Anktiva (nogapendekin alfa inbakicept-pmln) after receiving the US Food and Drug Administration’s green light for certain patients with non-muscle invasive bladder cancer (NMIBC).
The FDA approved Anktiva on 22 April in combination with Bacillus Calmette-Guérin (BCG) for patients with BCG-unresponsive NMIBC with carcinoma...
Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
